A Phase 2 interventional study of Niraparib in Solid Tumor, Breast Tumor and Colon Tumor, Malignant, sponsored by Tempus AI. Terminated at 80 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-29.
Sponsored by Tempus AI · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing niraparib in Breast Neoplasms — 6 open to participants now, 11 under way, 1 of them phase 3. niraparib · Breast Neoplasms.
Among the 20 studies testing niraparib in Breast Neoplasms, this one is the 11th largest by enrollment, is one of 2 that started in 2022, is one of 9 in phase 2, and was the 15th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →6 of the 20 studies testing niraparib in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:
Nagoya City University · Sites in Japan
Ages 18–80
Canadian Cancer Trials Group · Sites in Canada
GlaxoSmithKline · Sites in United States, Austria, Canada and 5 more countries
Ages 18+
QuantumLeap Healthcare Collaborative · Sites in United States
Ages 18+
Institut Paoli-Calmettes
Ages 18+
By country, each count listing its studies:
niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, niraparib is the treatment under test here. Read study by study →
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 12 · Phase 3 2
First in 2010; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 27 across the 20 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 20 have an industry lead sponsor. The 10 most frequent:
Tempus AI is the lead sponsor of 14 studies on the registry; 9 are open to participants now.
Tempus AI has 3 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies testing niraparib in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04641247GlaxoSmithKlineA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | 2026-12-28 |
| NCT03945721Massachusetts General HospitalA Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients | 2026-12-31 |
| NCT04837209Massachusetts General HospitalRadiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer | 2027-02-01 |
| NCT06535893Nagoya City UniversitySustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer | 2027-06-30 |
| NCT05519670Institut Paoli-CalmettesA Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 20 studies testing niraparib in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Niraparib
Eligible participants will receive daily dosing of Niraparib.
Also known as: Zejula
Overall Response Rate (ORR) - Independent Central Review (ICR)
To evaluate overall response rate (ORR) as assessed by Independent Central Review (ICR) using RECIST v1.1
Time frame: Up to 4 years
Duration of Response (DOR) - Independent Central Review (ICR)
To evaluate duration of response (DOR) as assessed by ICR using RECIST v1.1
Time frame: Up to 4 years
Progression-Free Survival (PFS) - Independent Central Review (ICR)
To evaluate progression-free survival (PFS) as assessed by ICR using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Time frame: Up to 4 years
Overall Response Rate (ORR) - Investigator
To evaluate ORR as defined as the proportion of patients who had a partial or complete response (PR or CR) to therapy, as assessed by Investigator using RECIST v1.1 and assessed periodically throughout the treatment period based on imaging every 8 weeks (56 ± 7 days).
Time frame: 2 years 3 months
Duration of Response (DOR) - Investigator
To evaluate DOR as assessed by Investigator using RECIST v1.1 defined as from first documentation of objective tumor response (CR or PR) to first documentation of objective tumor progression or death due to any cause.
Time frame: 2 years 3 months
Progression-Free Survival (PFS) - Investigator
To evaluate PFS as assessed by Investigator using RECIST v1.1 determined from the first dose to the date of first radiographic progression or death from any cause in the absence of progression, whichever occurred first, or were censored.
Time frame: 2 years 3 months
Clinical Benefit Rate (CBR) - Investigator and ICR
To evaluate Clinical Benefit Rate (CBR), defined as the percentage of patients who had achieved Complete Response (CR), Partial Response (PR), or Stable Disease (SD) for 8 weeks or more, as assessed by Investigator only (ICR not performed due to early study termination).
Time frame: 2 years 3 months
ORR With Untreated Measurable CNS Lesions - Investigator
To evaluate intracranial ORR in participants with untreated measurable CNS lesions as assessed by Investigator using RECIST v1.1
Time frame: Up to 4 years
ORR With Untreated Measurable CNS Lesions - ICR
To evaluate intracranial ORR in participants with untreated measurable CNS lesions as assessed by ICR using RECIST v1.1
Time frame: Up to 4 years
Number of Participants With Treatment-Emergent Adverse Events
To evaluate safety and tolerability per the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0)
Time frame: 2 years 3 months
Overall Survival (OS)
To evaluate overall survival (OS) defined as the time from the date of first dose of study drug to the date of death by any cause. Patients who were alive were censored at the date of last contact.
Time frame: 6 months and 12 months
| Milestone | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| Started | 22 |
| Completed | 16 |
| Not completed | 6 |
To evaluate overall response rate (ORR) as assessed by Independent Central Review (ICR) using RECIST v1.1
| Participants | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| Overall Response Rate (ORR) - Independent Central Review (ICR) | 0 |
To evaluate duration of response (DOR) as assessed by ICR using RECIST v1.1
| Participants | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| Duration of Response (DOR) - Independent Central Review (ICR) | 0 |
To evaluate progression-free survival (PFS) as assessed by ICR using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
| Participants | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| Progression-Free Survival (PFS) - Independent Central Review (ICR) | 0 |
To evaluate ORR as defined as the proportion of patients who had a partial or complete response (PR or CR) to therapy, as assessed by Investigator using RECIST v1.1 and assessed periodically throughout the treatment period based on imaging every 8 weeks (56 ± 7 days).
| Participants | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| Complete Response (CR) | 0 |
| Partial Response (PR) | 2 |
| Stable Disease (SD) | 5 |
| Progressive Disease (PD) | 5 |
To evaluate DOR as assessed by Investigator using RECIST v1.1 defined as from first documentation of objective tumor response (CR or PR) to first documentation of objective tumor progression or death due to any cause.
| Months | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| Duration of Response (DOR) - Investigator | NA (NA to NA) |
To evaluate PFS as assessed by Investigator using RECIST v1.1 determined from the first dose to the date of first radiographic progression or death from any cause in the absence of progression, whichever occurred first, or were censored.
| Months | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| Progression-Free Survival (PFS) - Investigator | 3.3 (1.7 to NA) |
To evaluate Clinical Benefit Rate (CBR), defined as the percentage of patients who had achieved Complete Response (CR), Partial Response (PR), or Stable Disease (SD) for 8 weeks or more, as assessed by Investigator only (ICR not performed due to early study termination).
| Participants | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| Clinical Benefit Rate (CBR) - Investigator and ICR | 6 (21.1 to 78.9) |
To evaluate intracranial ORR in participants with untreated measurable CNS lesions as assessed by Investigator using RECIST v1.1
| Participants | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| ORR With Untreated Measurable CNS Lesions - Investigator | 0 |
To evaluate intracranial ORR in participants with untreated measurable CNS lesions as assessed by ICR using RECIST v1.1
| Participants | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| ORR With Untreated Measurable CNS Lesions - ICR | 0 |
To evaluate safety and tolerability per the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0)
| Participants | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| Number of Participants With Treatment-Emergent Adverse Events | 22 |
To evaluate overall survival (OS) defined as the time from the date of first dose of study drug to the date of death by any cause. Patients who were alive were censored at the date of last contact.
| Percentage | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| Overall Survival at 6 Months | 81.8 (44.7 to 95.1) |
| Overall Survival at 12 Months | 51.9 (19.8 to 76.7) |
Collected over All adverse events (AEs) and serious adverse events (SAEs) were collected and recorded for each patient from the day of signing the main study informed consent form until 30 days after the last dose of study treatment up to 28 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations | 1/22 (4.5%) | 6/22 (27.3%) | 22/22 (100%) |
| Event | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/22 |
| AscitesGastrointestinal disorders | 1/22 |
| HaematocheziaGastrointestinal disorders | 1/22 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/22 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/22 |
| Multiple organ dysfunction syndromeGeneral disorders | 1/22 |
| SepsisInfections and infestations | 1/22 |
| AcidosisMetabolism and nutrition disorders | 1/22 |
| SeizureNervous system disorders | 1/22 |
| HypotensionVascular disorders | 1/22 |
| Event | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| NauseaGastrointestinal disorders | 10/22 |
| FatigueGeneral disorders | 10/22 |
| InsomniaPsychiatric disorders | 8/22 |
| AnaemiaBlood and lymphatic system disorders | 7/22 |
| Decreased appetiteMetabolism and nutrition disorders | 6/22 |
| DehydrationMetabolism and nutrition disorders | 6/22 |
| ConstipationGastrointestinal disorders | 5/22 |
| Platelet count decreasedInvestigations | 5/22 |
| DizzinessNervous system disorders | 5/22 |
| HeadacheNervous system disorders | 5/22 |
| Age, Categorical(Participants) | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 6 |
| >=65 years | 16 |
| Sex: Female, Male(Participants) | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| Female | 15 |
| Male | 7 |
| Race (NIH/OMB)(Participants) | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 16 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Ethnicity (NIH/OMB)(Participants) | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 21 |
| Unknown or Not Reported | 0 |
| Baseline Height(cm) | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| Mean | 166.5 ± 10.31 |
| Baseline Weight(kg) | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| Mean | 74.46 ± 19.663 |
| Baseline ECOG Performance Status(Participants) | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| ECOG 0 | 7 |
| ECOG 1 | 15 |
| Cancer Type(Participants) | Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations |
|---|---|
| Colon Cancer | 4 |
| Pancreatic Carcinoma | 4 |
| Breast Cancer | 3 |
| Gastric Cancer | 2 |
| Bile Duct Cancer | 1 |
| Endometrial Cancer | 1 |
| Glioma | 1 |
| Malignant Melanoma | 1 |
| Neuroendocrine Carcinoma | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Renal Cancer | 1 |
| Sarcoma | 1 |
| Uterine Cancer | 1 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2022 to primary completion in Aug 2024, 28 months.
Results were first posted in Oct 2025, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Niraparib
Tempus AI